Stock AVTE AEROVATE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Aerovate Therapeutics, Inc.

Equities

AVTE

US0080641071

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
21.75 USD +0.83% Intraday chart for Aerovate Therapeutics, Inc. -1.36% -3.89%
Apr. 12 Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing MT
Apr. 04 Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aerovate Therapeutics Insider Sold Shares Worth $334,478, According to a Recent SEC Filing
MT
Aerovate Therapeutics Insider Sold Shares Worth $300,033, According to a Recent SEC Filing
MT
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
AQ
Aerovate Therapeutics Q4 Loss Widens
MT
Aerovate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aerovate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
AQ
Aerovate Therapeutics Insider Sold Shares Worth $908,046, According to a Recent SEC Filing
MT
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
AQ
Aerovate Therapeutics, Inc. Announces Board Changes
CI
Aerovate Therapeutics : March 2024 Corporate Presentation
PU
Aerovate Therapeutics Insider Sold Shares Worth $165,628, According to a Recent SEC Filing
MT
Aerovate Therapeutics : December 2023 Corporate Presentation
PU
Aerovate Therapeutics Insider Sold Shares Worth $203,237, According to a Recent SEC Filing
MT
Aerovate Therapeutics Completes Enrollment in Phase 2b Portion of Trial for Treatment of Pulmonary Arterial Hypertension
MT
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2B Portion and Enrollment of First Patient into Phase 3 in the Impahct Trial Evaluating Av-101 for the Treatment of Pulmonary Arterial Hypertension
CI
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
AQ
Aerovate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
AQ
Aerovate Therapeutics : November 2023 Corporate Presentation
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AVTE Stock
  4. News Aerovate Therapeutics, Inc.